Oligonucleotide therapies for the lung: ready to return to the clinic?

Manish Kumar, Sterghios Moschos

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
4 Downloads (Pure)


The most promising targets for treating lung diseases are often intracellular molecules recalcitrant to conventional pharmacotherapy. In this respect, antisense oligonucleotides (ASO) would be valuable tools to treat airways disease, as the plurality of their potential mechanisms of action is well-established, their efficiency has been extensively validated in-vitro, and their potential clinical value has been demonstrated with numerous regulatory approvals.

Yet in spite of high confidence in the treatment rationale and mechanism of action, it appears that oligonucleotides delivered topically to the lung either rapidly access circulation via epithelial transcytosis or are removed by alveolar macrophages, exerting minimal if any action in the cytosol of cells relevant to lung disease. Moreover, use of cell penetrating peptides, liposomes or nanoparticle delivery systems has not so far been shown to eliminate circulatory clearance, may activate immune responses, or drive macrophage phenotypic changes that, together or in isolation, may present risks to patients.
Original languageEnglish
Pages (from-to)2604-2606
JournalMolecular Therapy
Issue number12
Early online date22 Nov 2017
Publication statusE-pub ahead of print - 22 Nov 2017


Dive into the research topics of 'Oligonucleotide therapies for the lung: ready to return to the clinic?'. Together they form a unique fingerprint.

Cite this